perhaps nothing you didn't already figureout yourselves,but..sexual dysfunction w AIs

[Lani]

seems to be more prevalent and severe than they thought

Menopause. 2012 Sep 17. [Epub ahead of print]
Sexual dysfunction in women on adjuvant endocrine therapy after
breast cancer.
Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS.
From the 1Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro, Sweden; Schools of 2School of Health and Medical Sciences, Örebro University, Sweden and 3School of Medicine, Örebro University, Örebro, Sweden; and 4Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Abstract
OBJECTIVE: The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors.
METHODS: A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire.
RESULTS: In all, 42.4% of aromatase inhibitor-treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitor-treated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns.
CONCLUSIONS: Our findings suggest that sexual dysfunction in aromatase inhibitor-treated women is a greatly underestimated problem.
PMID: 22990756